Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.